Array Biopharma Stays Ahead

According to this article in Forbes a combination of good study data results and effective partnerships should drive Array Biopharma's stock higher over the course of the next year. Just recently an analyst Ian Somaiya cited positive early-stage data for their type 2 Diabetes treatment, the drug met all safety goals.

Although it is still limited data, it provides support that their treatment is progressing. According to Somaiya, he has a price target on Array's share at $15, which is more than three times its current value. Will we see Array Biopharma skyrocket?

Share this article with your social network, just click below to share now!

Share |